Eli Lilly and Co.

Lilly's Alzheimer's finding triggers investor hope, doctor caution

August 27, 2012
Bloomberg News
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
More

Lilly wins appeal upholding patent for Alimta cancer drug

August 24, 2012
Bloomberg News
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
More

Alzheimer's drug results leave Lilly 'excited' but uncertain

August 24, 2012
J.K. Wall
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
More

Lilly's Alzheimer's drug trials show mixed results

August 24, 2012
Bloomberg News, J.K. Wall
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
More

Alzheimer's quest puts Lilly to test

August 11, 2012
J.K. Wall
Odds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
More

Lilly to book $790M Amylin payment in third quarter

August 9, 2012
Associated Press
Eli Lilly and Co. will book about $790 million in pretax income in the third quarter thanks to an early payment from former drug development partner Amylin Pharmaceuticals.
More

Lilly stock slips after competitors halt Alzheimer's plans

August 7, 2012
 IBJ Staff and Bloomberg News
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
More

Lilly braces for decline in Europe

July 30, 2012
J.K. Wall
Austerity and upheaval in Europe have not hurt Eli Lilly and Co.’s $4 billion-a-year drug business there, but the company is moving forward with plans to survive a coming swoon anyway.
More

Lilly's quarterly profit falls, but tops analyst expectations

July 25, 2012
Bloomberg News
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
More

Potential Alzheimer’s drug fails first of four key trials

July 24, 2012
Bloomberg News
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.
More

Potential Lilly antipsychotic falls short in study

July 11, 2012
Associated Press
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
More

Competing Alzheimer's treatments facing long odds

July 11, 2012
Bloomberg News
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer's, rather than just its symptoms. Analysts say the potential drugs are long shots.
More

Lilly gets 6-month Cymbalta marketing extension

July 6, 2012
Associated Press
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
More

Lilly cancer treatment fails trial in stomach cancer

July 5, 2012
 IBJ Staff and Bloomberg News
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
More

Bristol-Myers to buy former Lilly partner Amylin for $5.3B

June 30, 2012
Bloomberg News
Bristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment to Eli Lilly and Co. of about $1.7 billion.
More

Life sciences hold up in recession

June 25, 2012
J.K. Wall
A new report shows Indiana’s life sciences companies performed better than their peers around the country—and far better than the rest of Indiana’s private sector—during the early phases of the economic downturn.
More

J&J, Bayer fail to win U.S. OK for expanded Xarelto use

June 22, 2012
If approved for acute coronary syndrome, Xarelto would compete with Effient from Indianapolis-based Eli Lilly and Co and Brilinta from London-based AstraZeneca Plc.
More

Lilly resumes $3B stock buyback program, declares dividend

June 19, 2012
Associated Press
The local pharmaceutical giant plans to complete the program started in 2000 by repurchasing $420 million in shares by the end of the year. And on Tuesday, it declared a regular dividend of 49 cents.
More

Largest Indiana public companies mostly fared well in 2011Restricted Content

June 16, 2012
Performance varied widely as industries ebbed, flowed.
More

Web domain requests include .Cialis, .Walmart

June 14, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. and other corporate heavyweights are applying for Web suffixes including .cialis, .walmart and .jpmorgan under a program to expand the number of Internet domain names beyond .com.
More

Lilly sinks $20M into Chinese firm for 'branded generic' drugs

June 12, 2012
J.K. Wall
Eli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio of branded generic medicines in the fast-growing Asian market.
More

Lilly chases Novo in insulin race

June 11, 2012
J.K. Wall
Eli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.
More

Good cholesterol may not lower heart risk, study suggests

May 17, 2012
Bloomberg News
Raising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
More

U.S. losing drug-research jobs to other countries

May 17, 2012
Bloomberg News
Eli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore, Ireland and South Africa boost incentives.
More

Lilly unlikely to gain from Plavix patent loss, analyst says

May 17, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT